INDUSTRY × Observational × Head and Neck Neoplasms × Clear all DP-04
Recruiting
100 enrolled
CAMPERR
Recruiting
7,000 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
ELEPHAS-02
Recruiting
416 enrolled
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
Active not recruiting
1,150 enrolled
SYMTECH01
Completed
33 enrolled
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Completed
662 enrolled
PREMIER
Recruiting
500 enrolled
DESCENT-1
Enrolling by invitation
400 enrolled
ProNiHN
Completed
502 enrolled
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
Completed
485 enrolled
Tempus Priority Study: A Pan-tumor Observational Study
Active not recruiting
1,000 enrolled
PREFER
Completed
1,429 enrolled
ETCETERA
Not yet recruiting
80 enrolled
Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Completed
43,994 enrolled
Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences
Not yet recruiting
500 enrolled
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Terminated
22 enrolled
DETECT
Completed
458 enrolled
Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread
Completed
262 enrolled
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
Completed
1,160 enrolled
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Unknown
279 enrolled
PIONEER
Unknown
1,000 enrolled
Study to Evaluate the Safety of Nanoxel M Inj.
Unknown
1,498 enrolled
Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada
Completed
591 enrolled
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Completed
221 enrolled
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Withdrawn
LORHAN
Completed
26,000 enrolled